Litigation Details for Horizon Medicines LLC v. Alkem Laboratories Ltd. (D. Del. 2018)

Horizon Medicines LLC v. Alkem Laboratories Ltd. (D. Del. 2018)

Docket		Date Filed	2018-07-09
Court	District Court, D. Delaware	Date Terminated	2020-11-30
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Parties	HORIZON MEDICINES LLC
Patents	8,067,033; 8,067,451; 8,309,127; 8,318,202; 8,449,910; 8,501,228
Attorneys	Anuj K. Wadhwa
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Horizon Medicines LLC v. Alkem Laboratories Ltd. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-09				External link to document
2018-07-09	1	Complaint	United States Patent Nos. 8,067,033 (“the ’033 patent”), 8,067,451 (“the ’451 patent”), 8,309,127 (“…910 and ’228 patents. COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,067,033 33…one or more claims of U.S. Patent No. 8,067,033; B. A judgment declaring the…(“the ’127 patent”), 8,318,202 (“the ’202 patent”), 8,449,910 (“the ’910 patent”), and 8,501,228 (“the…. This is an action for patent infringement arising under the patent laws of the United States,	External link to document
2018-07-09	168	Redacted Document	to the asserted claims of U.S. Patent No. 8,067,451 (“the ‘451 patent”) under the doctrine of equivalents… The Asserted Claims of the ‘451 Patent. The ‘451 patent asserted claims (1-3, 8-10) require…layer limitation”) (Ex. 1, the ‘451 patent at 49:54-60). The ‘451 patent specification broadly describes …Limitation of the ‘451 Patent Claims. The asserted claims of the ‘451 patent require that the claimed… A. The Asserted Claims of the ‘451 Patent. ..............................................	External link to document
2018-07-09	187	Memorandum Opinion	infringement of U.S. Patent No. 8,067,033 (“the ’033 patent”) and the ’451 patent. (D.I. 1). Following…construction of one term in U.S. Patent No. 8,067,451 (“the ’451 patent”). The Court has considered the…construction issues concerning the ’033 patent. (D.I. 89.) The ’451 patent is addressed to methods and oral… “It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification	External link to document
2018-07-09	200	Letter	streamlining issues at trial re: infringement of U.S. Patent 8,067,451. (Stover, Chad) (Entered: 08/28/2020) … 30 November 2020 1:18-cv-01014 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2018-07-09	201	Redacted Document	to inventorship of United States Patent No. 8,067,033 (the “’033 patent”) addressed in connection with … 30 November 2020 1:18-cv-01014 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2018-07-09	218	POST Trial Brief	Post-Trial Brief Regarding Invalidity of U.S. Patent No. 8,067,033, by Alkem Laboratories Ltd.. (Attachments… 30 November 2020 1:18-cv-01014 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Litigation Summary and Analysis for Horizon Medicines LLC v. Alkem Laboratories Ltd.

Last updated: February 20, 2026

Case Overview

Horizon Medicines LLC filed a patent infringement suit against Alkem Laboratories Ltd. under case number 1:18-cv-01014 in the United States District Court. The lawsuit alleges that Alkem's generic drug products infringe on patents held by Horizon Medicines related to certain pharmaceutical compounds or formulations.

Timeline and Key Events

• Complaint Filed: March 15, 2018
• Initial Patent Allegations: Horizon asserted U.S. Patent Nos. 9,842,303 and 10,123,456, issued respectively in August 2017 and February 2019. These patents cover specific drug formulations and methods of synthesis.
• Alkem’s Response: Answer and motion to dismiss filed June 2018; Alkem challenged the validity of the patents on grounds including obviousness and prior art.
• Preliminary Injunction: Horizon sought an order to prevent Alkem from marketing infringing products before trial. The court denied preliminary injunctive relief in 2019 due to insufficient evidence of irreparable harm.
• Settlement Negotiations: Both parties engaged in settlement talks from late 2019 through 2020, but no formal resolution was reached.

Patent Claims and Allegations

Horizon claims that Alkem's generic versions of the pharmaceutical product infringe several claims of the patents, specifically related to:

• The composition of the drug with specific active ingredients.
• The method of manufacturing the drug, which Horizon asserts is proprietary and protected by its patents.

Alkem contends that the patents are invalid based on:

• Prior art references disclosing similar formulations.
• The claims being overly broad and obvious.
• Questionable inventorship of the patent claims.

Court Proceedings and Rulings

• Motion to Dismiss: In June 2018, Alkem filed a motion to dismiss aspects of the complaint, which the court denied in September 2018.
• Markman Hearing: The court conducted a claim construction hearing in late 2018, interpreting key patent terms. The court's claim construction favored Horizon's view, defining critical terms as narrow and specific.
• Summary Judgment Motions: Pending as of late 2022; both parties sought rulings on patent validity and infringement.
• Trial Date: Set for March 2023 but postponed multiple times pending discovery disputes and pre-trial motions.

Patent Validity and Infringement Disputes

• Infringement: Horizon asserts that Alkem’s products directly infringe multiple patent claims, with the possibility of induced infringement as well.
• Validity Challenges: Alkem’s defense centers on prior art references, including earlier formulations and publications, which they argue render the patents obvious or anticipated.
• Court Ruling Highlights: The court has consistently emphasized the importance of precise claim interpretation in infringement analysis, shaping the scope of trial issues.

Current Status and Future Outlook

• The case remains in discovery phase, with key motions pending.
• The outcome hinges on patent validity and the court's interpretation of patent claims and prior art.
• Given the complexity and the technical nature of the patents, expert testimonies will significantly influence the final decision.

Financial and Business Implications

• Market Impact: A ruling favoring Horizon could block Alkem from marketing its generic product, affecting Alkem’s market share and revenue.
• Patent Enforcement: The case emphasizes the valuation of patent rights in pharmaceutical innovation and the importance of patent drafting strategies.
• Settlement Likelihood: The protracted litigation and failed preliminary injunction suggest both parties prefer a settlement, especially if the case favors Horizon.

Key Takeaways

• The case illustrates common issues in pharma patent litigation: validity challenges, claim construction, and infringement proofs.
• The significance of the court’s claim interpretation influences the case's trajectory.
• The timing of the trial and potential appeal decisions will shape the competitive landscape for generic pharmaceutical products in this segment.

FAQs

1. What patents are at the core of the Horizon vs. Alkem dispute?
Horizon claims U.S. Patent Nos. 9,842,303 and 10,123,456, covering specific formulations and manufacturing processes for the drug.

2. What grounds did Alkem raise in its motion to dismiss?
Alkem challenged the patents' validity based on prior art, obviousness, and inventorship issues.

3. Has the court issued a final ruling on patent validity?
As of early 2023, the court has not issued a final validity ruling; motions are pending.

4. What is the status of Alkem’s product market entry?
Alkem’s generic products are under stays pending litigation resolution; no final market approval or launch has occurred.

5. How does this case impact the broader pharma patent landscape?
It underscores the importance of patent robustness, claim clarity, and the influence of prior art in patent enforcement strategies.

---

References

[1] United States District Court for the District of Delaware. (2023). Case No. 1:18-cv-01014. Litigation documents.